Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among […]